Testing a new medication combined with standard chemotherapy for advanced pancreatic cancer

Plain-English translation of NCT06904378 on ClinicalTrials.gov ↗ · Source last updated May 2026 · Translation generated June 2026 · How we translate trials

Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.

What is this trial?

This trial is testing a new medication called combined with two standard chemotherapy drugs ( and nab-paclitaxel) for people with advanced pancreatic cancer that has stopped responding to their first treatment. The researchers believe this medication may help your immune system fight the cancer more effectively. Half the participants will receive the new treatment, and half will receive the standard chemotherapy alone so the researchers can compare how well each works.

Pancreatic cancer is very difficult to treat, and many patients develop resistance to their first round of chemotherapy. This medication may help reprogram the tumor environment to make cancer cells more vulnerable to treatment and boost the body's natural cancer-fighting ability.

Do you qualify?

You likely qualify if…

you have been diagnosed with advanced pancreatic cancer that has progressed or stopped responding to your first-line chemotherapy treatment
you have measurable or evaluable cancer (visible on scans or confirmed through testing)
you are at least 18 years old and in reasonably good health overall
you have adequate blood cell counts and normal kidney, liver, and bone marrow function as determined by blood tests
you are willing to use effective contraception during treatment and for several months afterward (the medication may harm a developing fetus)

You likely don't qualify if…

you have received more than one line of chemotherapy treatment for your advanced pancreatic cancer, or you have already received gemcitabine or nab-paclitaxel for advanced disease
you have had major surgery requiring general anesthesia within the past 4 weeks
you have received chemotherapy, immunotherapy, or radiation therapy within the past 2 weeks
you are currently taking alternative or botanical cancer treatments
you have a history of other cancers (with limited exceptions for cancers treated more than 2 years ago)

What participation looks like

You will take the new medication by mouth twice daily for 21 days out of every 28-day cycle, while also receiving the standard chemotherapy drugs intravenously on days 1, 8, and 15 of each cycle. The trial has two phases: in Phase 1, researchers will find the right dose of the new medication; in Phase 2, you'll either receive the medication plus chemotherapy, or chemotherapy alone. You'll have regular clinic visits and blood tests to monitor your cancer and how well you're tolerating treatment.

AI-generated summary from trial data · Jun 18, 2026 · Not medical advice

Trial locations(1 site)

United States

Washington University School of Medicine, St Louis, Missouri